About Brensocatib API
Therapeutic CategoryPulmonology
CAS Number
1802148‑05‑5
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Brensocatib inhibits dipeptidyl peptidase‑1 (DPP1), an enzyme responsible for activating neutrophil serine proteases (NSPs).
By inhibiting DPP1, it prevents activation of neutrophil elastase, proteinase‑3, and cathepsin‑G in neutrophil precursors.
This leads to:
Reduced neutrophil‑driven airway inflammation
Decreased lung tissue damage
Lower frequency of pulmonary exacerbations
Acts upstream of inflammation, unlike symptomatic anti‑inflammatory therapies.
Indication
Treatment of non‑cystic fibrosis bronchiectasis (NCFB) in:
Adult and pediatric patients ≥12 years of age
Related APIs
Brensocatib
Pulmonology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.